ESMO shared on LinkedIn:
“First-line combination of tiragolumab plus atezolizumab and chemotherapy failed to improve progression-free survival (PFS) and overall survival (OS) compared to standard therapy in patients with locally advanced unresectable or metastatic non-squamous NSCLC, according to the results from the SKYSCRAPER-06 study presented at ESMOImmuno24
Read the full news on ESMO Daily Reporter.”
